NEXGEL Preliminary Revenue For Q3 2024 Of ~$2.85M, An Increase Of ~133% YoY, As Well As An Increase Of ~30% Over The Company's Previously Issued July Q3 Revenue Guidance Of $2.20M

Author: Benzinga Newsdesk | October 10, 2024 08:01am

NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced preliminary, unaudited expected record revenue for the third quarter 2024 of approximately $2.85 million, an increase of approximately 133% year-over-year and approximately 98% quarter-over-quarter, respectively, as well as an increase of approximately 30% over the Company's previously issued July third quarter revenue guidance of $2.20 million.

Posted In: NXGL